TENX
Tenax Therapeutics Inc (TENX)
Healthcare • NASDAQ • $11.66+0.09%
- Symbol
- TENX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $11.66
- Daily Change
- +0.09%
- Market Cap
- $300.54M
- Trailing P/E
- N/A
- Forward P/E
- -7.98
- 52W High
- $18.38
- 52W Low
- $5.34
- Analyst Target
- $29.71
- Dividend Yield
- N/A
- Beta
- 1.00
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Company websiteResearch TENX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.